Stockholders protest Pfizer's drug prices

Lenzer, Jeanne
July 2004
CMAJ: Canadian Medical Association Journal;7/6/2004, Vol. 171 Issue 1, p24
Academic Journal
Reports on the criticism of the Interfaith Center on Corporate Responsibility (ICCR) against the pricing practices of a number of drug companies. Proposal on drug access submitted by ICCR at Pfizer's annual meeting in 2004; Statement from Adrian Dominican Sisters' coordinator Margaret Weber about the proposal; Position of Pfizer chairman Henry A. McKinnell Jr. regarding the ICCR proposal; Contributions of Pfizer to political action committee and campaign funds.


Related Articles

  • COMPANY SPOTLIGHT: Pfizer.  // PharmaWatch: CNS;February 2003, Vol. 2 Issue 2, p18 

    Presents a corporate profile of pharmaceutical company Pfizer. Company overview; Business description; Key employees including president and chairman Henry A. McKinnell and vice-president John F. Niblack; Strengths and weaknesses; Financial status; Products and services.

  • Pfizer to explain high cost of prescription drugs. Rosa, Taina // Caribbean Business;9/16/2004, Vol. 32 Issue 39, p18 

    Reports on the seminar aimed at explaining the reason for the high cost of medicine offered by pharmaceutical manufacturer, Pfizer Corp. in Puerto Rico. Outlook of the industry towards the high prices of medicine; Cost associated with developing a single product; Investments involved in research...

  • Nexium 24HR's impact: How top brands respond.  // Drug Store News;8/25/2014, Vol. 36 Issue 8, p26 

    The article focuses on how drug retailers and consumers have been affected by the introduction of the Nexium 24HR over-the-counter (OTC) acid blocker by pharmaceutical company Pfizer Inc. Topics discussed include the decline of the dollar sales of the competitors of Nexium, the increase of the...

  • Pfizer takes leading role in drug-price debate. Arnold, Matthew // Medical Marketing & Media;Aug2004, Vol. 39 Issue 8, p32 

    Reports on the launch of Helpful Answer, the brand for beefed-up roster of patient assistance programs by Pfizer Inc. in the U.S. Effort of the pharmaceutical industry to alleviate the high cost of drugs to uninsured Americas; Leadership role of Pfizer Inc. in drug-price debate; Expansion of the...

  • TOP STORIES.  // MondayMorning;3/10/2008, Vol. 16 Issue 10, p1 

    Monday, March 10, 2008 / Vol. 16 / No. 10 MondayMorning Weekly Online News Update for the Healthcare Industry Monday, March 10, 2008 / Vol. 16 / No. 10 ©2008 MedContent, Inc / All Rights Reserved TOP STORIES Brand-Name Drugs Continue Sharp Price Increases. Drugmakers increased their...

  • Market watch: Pricing strategies for emerging markets. Lineberry, Neil; Snyder, Eric; Gunda, Seema // Nature Reviews Drug Discovery;Aug2011, Vol. 10 Issue 8, p567 

    The article focuses on pricing strategies for pharmaceutical products in emerging markets. It states that identifying prices is a key challenge if one has to consider the annual income of the patient over the cost of his therapy. It mentions examples of pricing strategies employed on various...

  • Pharm Exec's 7th Annual Media Audit. Sillup, George; Porth, Stephen // Pharmaceutical Executive;Mar2011, Vol. 31 Issue 3, p20 

    The article presents the view of the author on the negative issues in 2010 involving the pharmaceutical industry which has caught the attention of the mass media in the U.S. According to the author, the coverage of the media on flu vaccinations were recounting, while the focus on the high prices...

  • Regulatory & Healthcare News.  // PharmacoEconomics & Outcomes News;11/13/2010, Issue 616, p10 

    This section presents updates on drug regulation and health care. Decision Resources reported that humira is the market leader for psoriatic arthritis treatment. Pharmac and Pfizer signed a multiproduct agreement for the funding of sunitinib and varenicline in New Zealand. The manufacturer's...

  • Public address. Kelly, Patrick // Medical Marketing & Media;May2004, Vol. 39 Issue 5, p12 

    Reports that Pfizer president Patrick Kelly responded when "The Wall Street Journal" accused pharmaceutical companies of price increases that would wipe out gains in pharmaceutical benefits for low-income seniors covered by Medicare. Kelly's contention that the article gave a distorted view of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics